PROCTER & GAMBLE WINS PATENT INFRINGEMENT LAWSUIT FOR OSTEOPOROSIS THERAPY ACTONEL
CINCINNATI February 28, 2008 — Today the United States District Court of Delaware ruled in favor of The Procter & Gamble Company (P&G) in the patent infringement lawsuit filed by P&G against Teva Pharmaceuticals USA, Inc. The positive ruling protects P&G’s rights in the U.S. to exclusively market the osteoporosis therapy Actonel® (risedronate sodium tablets).
Dong Wha and Procter & Gamble Pharmaceuticals form alliance for Osteoporosis treatments
Seoul, Korea, July 2, 2007 — Dong Wha Pharmaceutical Ind. Co, (Korea Exchange: 000020) and Procter & Gamble Pharmaceuticals, Inc. (P&GP), a subsidiary of The Procter & Gamble Company (NYSE: PG), today announced a strategic alliance under which P&GP will have rights to develop and commercialize a novel class of molecules for the treatment of osteoporosis. The agreement includes Dong Wha's novel drug DW1350 and a family of back up compounds.
Procter & Gamble Pharmaceuticals recevies Alliance Excellence Award from the Association of Strategic Alliance Professionals
CINCINNATI, Feb.15, 2007 — Procter & Gamble Pharmaceuticals, Inc. (PGP), a division of The Procter & Gamble Company (NYSE: PG), today announced it is a recipient of the 2007 Alliance Program Excellence Award, presented by the Association of Strategic Alliance Professionals (ASAP). The award recognizes and celebrates companies worldwide that have achieved dramatic success through their alliances and alliance programs.
Procter & Gamble Pharmaceuticals and ARYX Therapeutics Form Alliance For an Investigational Treatment for Gastrointestinal Disorders
Cincinnati, Ohio, and Fremont, California, July 11, 2006 — Procter & Gamble Pharmaceuticals, Inc., a division of The Procter & Gamble Company (NYSE: PG) and ARYx Therapeutics, a private drug discovery and development company, today announced a strategic alliance under which P&G will develop and commercialize ARYx's novel drug, ATI-7505, for the treatment of gastrointestinal disorders such as gastroesophageal reflux disease (GERD) and gastroparesis (delayed emptying of the stomach).
Procter & Gamble Pharmaceuticals And Sanofi-Aventis US LLC File Lawsuit Against Roche Pharmaceuticals And GlaxoSmithKline
Wednesday, January 4, 2006 — On Wednesday, January 4, 2006, Procter & Gamble Pharmaceuticals and sanofi-aventis US LLC , a member of the sanofi-aventis Group, co-marketers of Actonel® (risedronate sodium tablets), filed a lawsuit under the Lanham Act against Roche Pharmaceuticals and GlaxoSmithKline in the United States Federal District Court in the Southern District of New York.
The U.S. Food And Drug Administration Approves Actonel® With Calcium
Cincinnati, OH, Bridgewater, NJ, (August 15, 2005) — On Friday, August 12 2005, the U.S. Food and Drug Administration (FDA) approved Actonel with Calcium (risedronate sodium tablets with calcium carbonate tablets, USP), a product that provides the fracture protection of Actonel tablets conveniently packaged with calcium tablets.
Procter & Gamble Selects Evotec as Provider of Pharmaceutical Discovery and Chemical Development Services
Hamburg, Germany | Oxford, UK — Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) and Procter & Gamble Pharmaceuticals, Inc. (PG&P), a subsidiary of The Procter & Gamble Company (NYSE – PG), today announced that they have entered into agreements whereby Evotec will provide pharmaceutical discovery and chemical development services to P&GP. Under the terms of the agreements, P&GP will access a wide range of discovery and preclinical expertise offered by Evotec, ranging from assay development, screening, medicinal and computational chemistry to scale-up and pharmaceutical manufacture.
Novartis and Procter & Gamble enter into commercialization agreement for Enablex®
East Hanover, NJ and Cincinnati, OH, July 6, 2005 — Novartis Pharmaceuticals Corporation and Procter & Gamble Pharmaceuticals, Inc. (P&GP), a division of The Procter & Gamble Company, today announced that they have entered into an agreement for the co-promotion and further development of Enablex® (darifenacin) extended release tablets for the treatment of overactive bladder (OAB) in the United States.
Panel Of Experts Agree That Bone Mineral Density Is No Longer Enough
Geneva, Switzerland, 28 June, 2005 — The Alliance for Better Bone Health announced today that according to evidence presented by an international panel of osteoporosis experts, Bone Mineral Density (BMD) testing does not accurately reflect all factors important to bone strength.
Inside the Calcium Conundrum: Women may not take the proper amount of calcium or they may take it incorrectly
Cincinnati, OH — Bridgewater NJ (June 13, 2005) - According to a new survey commissioned by The Alliance for Better Bone Health and conducted by Harris Interactive®, 83 percent of U.S. women aged 50 years and older who used a bisphosphonate (a prescription medication for osteoporosis) believe that taking a calcium supplement is very important in addition to calcium intake from dairy or food.
Procter & Gamble Licenses MetaCore and MetaBase from GeneGo
St. Joseph, Michigan (May 9th, 2005) - GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Procter & Gamble Pharmaceuticals, Inc., a subsidiary of The Procter & Gamble Company (NYSE — PG), has licensed MetaCore™ and MetaBase™ from GeneGo. MetaCore is a manually curated, proprietary human database with the ability to work with rat, mouse, fly, yeast and worm orthologs.
7TM Pharma signs research agreement with Procter & Gamble
Denmark - (April 12, 2005) - 7TM Pharma announced an agreement with Procter & Gamble Pharmaceuticals, Inc. (P&GP), a subsidiary of The Procter & Gamble Company (NYSE: PG), under which the parties will undertake a joint research program within therapeutic angiogenesis with the aim of identifying development candidates for treatment of diseases such as peripheral vascular diseases and coronary vascular disease related to arteriosclerosis.
Cincinnati Children's and Procter & Gamble Reach Licensing Agreement for Potential Heart Failure Treatment
Cincinnati - (February 22, 2005) - Cincinnati Children's Hospital Medical Center and Procter & Gamble Pharmaceuticals (P&GP), a division of the Procter & Gamble Co. (NYSE:PG), have reached a licensing agreement for a potential treatment for heart failure — commonly referred to as congestive heart failure.
TaiGen Biotechnology Announces Strategic Agreement with Procter & Gamble
Taipei, Taiwan - (January 6, 2005) - TaiGen Biotechnology Co., Ltd. announced today the signing of a strategic alliance relationship with Procter & Gamble Pharmaceuticals (P&GP) to further the development and commercialization of a novel non-flourinated quinolone antibiotic, invented by P&GP.
Actonel Provides Vertebral Fracture Risk Reduction in Women With Postmenopausal Osteoporosis at Risk for Upper GI Side Effects
San Antonio, TX (October 18, 2004) - Actonel® (risedronate sodium tablets) reduces the risk of vertebral fracture up to 62 percent at one year in women with postmenopausal osteoporosis who are at risk for upper gastrointestinal (GI) side effects, according to new analyses presented today at the American College of Rheumatology (ACR) annual meeting.
Actonel® Reduces Vertebral and Nonvertebral Fracture Risk in Postmenopausal Women with Osteopenia
WASHINGTON, DC (October 6, 2004) - A new analysis shows that Actonel® (risedronate sodium tablets) treatment up to three years significantly reduces the risk of vertebral and nonvertebral fragility fracture by 75 percent in postmenopausal women with osteopenia.
Image Metrics announces completion of knee analysis project for Procter & Gamble
Manchester, UK - 8th July 2004 - Image Metrics today announced the completion of a ground breaking project to provide software to analyse x-ray images of the knee for Procter & Gamble Pharmaceuticals, a global leader in treatments for bone disease.
Vita Embarks on a New Era in the Spanish Pharmaceutical Market as a Procter & Gamble Company
July 2, 2004 - Sant Joan Despí, Barcelone - - Procter & Gamble Pharmaceuticals today announced the close of its acquisition of the commercial business of Grupo Vita in Spain.
Are You Less Likely to be Truthful About Your Weight, Age, or Height?
June 21, 2004 - Cincinnati, Ohio and Bridgewater, N.J - A new survey reveals that women 40 years and older are less likely to be truthful about their weight
Untreated Postmenopausal Women with Osteoporosis are at Risk for First Spinal Fracture Within One Year
April 28, 2004 - BOSTON, MA - Results of a new analysis found that, without treatment, one out of 13 postmenopausal osteoporotic women who were initially fracture-free were likely to experience a spinal fracture within one year.
Genzyme Grants Exclusive License to Procter & Gamble to Develop RDP58 for Gastrointestinal Disorders
April 1, 2004 - Cambridge, MA and Cincinnati, OH - P&GP continues to advance the IBD field through ongoing clinical trials, substantial funding of IBD research, and innovative patient education and awareness programs.
Innovative Actonel 35mg Dosepak® Receives Best of Show at 2003 AmeriStar Awards
October 1, 2003 - Cincinnati, OH - The Best of Show award is given to the best new package execution in all packaging categories including food, beverage, health and beauty aids, pharmaceuticals, household products, and electronics.
Actonel® Helped Preserve Bone Quality at Five Years, New Data Show
September 22, 2003 - Minneapolis, MN - Actonel is the only osteoporosis therapy for which these aspects of bone quality have been evaluated in bone biopsies taken from the same patients before and after five years of treatment.
In a New Observational Analysis, Risedronate Significantly Reduced Nonvertebral Fracture Risk Compared To Alendronate And Nasal Calcitonin At One Year
September 22, 2003 - Minneapolis, MN - "Fracture reduction is the clinically relevant endpoint for evaluating osteoporosis therapies," said Nelson B. Watts, MD, presenting author and Director, University of Cincinnati Bone Health and Osteoporosis Center.
Study Shows Measurable Drop in Testosterone in Women Approaching Menopause
June 20, 2003 - PHILADELPHIA - Data from a large sample of pre-menopausal women confirm that testosterone levels decrease with age as healthy women near menopause.
Actonel® Provides Low Incidence of Vertebral Fracture in Osteoporosis Patients Through 7 Years
June 19, 2003 - PHILADELPHIA - "Osteoporosis is treated over a number of years, so long-term protection against fractures is critical," said Jean-Marc Kaufman, M.D., PhD, Unit for Osteoporosis and Metabolic Bone Disease, Ghent University Hospital, Belgium.
Data Show Bone Mineral Density Explains Only Small Portion of Nonvertebral Fracture Risk Reduction
June 19, 2003 - CINCINNATI, OH - "These results underscore the importance of physicians evaluating osteoporosis therapies based upon fracture reduction data," said Nelson B. Watts, MD, presenting author and Director, University of Cincinnati Bone Health and Osteoporosis Center.
New Evaluation of Osteoporosis Therapies Finds Gastrointestinal-related Cost Differences
May 15, 2003 - SAN DIEGO, CA - Actonel® Patients Had Fewer Gastrointestinal-related Medical Visits than Fosamax Patients
Women Pledge To Make Osteoporosis Matter
April 30, 2003 - CINCINNATI, OH; BRIDGEWATER, NJ - National education program highlights the importance of preventing fractures and takes osteoporosis education to new heights
Actonel Significantly Reduced Osteoporotic Fractures in High-Risk Postmenopausal Women At One Year
February 10, 2003 - CINCINNATI, OH; BRIDGEWATER, N.J. - Risk of Spinal Fracture Reduced by Up to 62 Percent
New Data Show Actonel® Reduced Nonvertebral Fracture Risk By 74 Percent In One Year, Significant Reduction As Early As 6 Months
June 21, 2002 - SAN FRANCISCO, CA - Further Evidence of Rapid Fracture Benefits with Actonel
Bone Microarchitecture Can Significantly Deteriorate in One Year in Early Postmenopausal Women, Despite Only Modest BMD Loss
June 21, 2002 - SAN FRANCISCO, CA - Research suggests Actonel protects microarchitecture in one year of treatment
UC Researcher Utilizes Historical Control Group For New Osteoporotic Fracture Analysis
June 19, 2002 - CINCINNATI, OH - Innovative new method for analyzing fracture efficacy
New Clinical Trials Will Explore Treatment to Improve Sexual Desire
June 18, 2002 - CINCINNATI, OH - Participants sought for a research study of investigational therapy for menopausal women who have experienced a decline in sexual interest
Study Shows Actonel® Reduces Vertebral Fracture Risk 70 Percent In Patients On Chronic Steroid Therapy
October 24, 2001 - LAS VEGAS NEV. - Bisphosphonates Recommended by American College of Rheumatology (ACR) for Glucocorticoid-Induced Osteoporosis (GIO)
American Academy of Pharmaceutical Physicians Announces Honorary Membership Awards
October 16, 2001 - APEX, NC - Dr. Ahonkhai today announced Dr. Richard Whitley and Dr. James H. Powell as this year's Honorary Membership Award recipients.
New Data Show Actonel® Reduced Clinical Vertebral Fractures In As Early As Six Months
October 13, 2001 - PHOENIX - Findings provide further evidence that Actonel prevents vertebral fractures fast
America's Favorite TV Mom Joins Lawmakers and Health Care Professionals to Rally for Diagnostic Osteoporosis Testings
May 1, 2001 - WASHINGTON, D.C. - Proposed Bill to Provide Affordable Screening and has Potential to Save Health Care System Billions Annually
JAMA Article Underscores Risk in Delaying Osteoporosis Diagnosis and Treatment
January 17, 2001 - WEST HAVERSTRAW, NY - A vertebral fracture is a warning signal; 1 in 5 women with postmenopausal osteoporosis who suffer a vertebral fracture will fracture again within just one year
|
